Nicox (LTS:0RCQ) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


LTS:0RCQ Nicox SA LTS:0RCQ
40 GF Score
Price €0.37
GF Value €0.71
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nicox Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nicox's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0RCQ vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Nicox's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nicox's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0RCQ
40GF Score
Nicox SA LTS:0RCQ
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nicox (LTS:0RCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of €0.37 is trading 48.2% below its estimated GF Value™ of €0.71. GuruFocus considers Nicox to be Possible Value Trap.

Key valuation signals for LTS:0RCQ:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.71 vs. price of €0.37 (48.2% below fair value)
  • GF Score™: 40/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Other Exchanges ALCOX:FranceNXOA:Germany
Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
40GF Score

Get the complete analysis for LTS:0RCQ

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€0.71
GF Value